Research
What the documents actually say.
Two things get written here. One is an investigation, run over the seller record this site maintains, into a question the market would rather leave vague. The other is a close reading of the trial literature on a specific drug or risk. Neither is a news summary, and neither goes out with a number we could not trace to the document it came from.
Research formats
Related tools
- Data investigation6 min · 1 sources
GLP-1 Telehealth Cancellation and Refund Policies
Most sellers let you stop on a monthly plan. Few refund medication once it ships, some lock you into three months up front, and many publish no refund terms at all.
Read the analysis→ - Data investigation10 min · 16 sources
Are Peptides Legal? What FDA’s 2026 Lists Say
BPC-157, TB-500 and MOTS-c left FDA’s Category 2 table for a “withdrawn” list, which gives no compounding route. FDA’s July 2026 briefings weigh against adding them. Status table, research-use-only rules, tesamorelin.
Read the analysis→ - Data investigation7 min · 11 sources
Tirzepatide With Glycine, B6 or Niacinamide
Glycine, B6 and niacinamide are an amino acid and two vitamins mixed in by the pharmacy. No human study shows they add a benefit, and FDA has written about compounded combinations.
Read the analysis→ - Scientific deep-dive7 min · 4 sources
Wegovy Pill Side Effects: What the Tablet Label Reports
The FDA label says the tablet's common side effects were similar to the injection's. This sets out the label's figures, the tablet-only numbers beside the injection's, what dysesthesia means, and how to take the pill.
Read the analysis→ - Data investigation7 min · 6 sources
Wegovy Pill Cost: Every Dose and Every Way to Pay
NovoCare self-pay by strength, the commercial savings offer and its $100 cap, the Medicare GLP-1 Bridge, what telehealth sellers add on top, and the pill against the injection per day.
Read the analysis→ - Scientific deep-dive8 min · 10 sources
Sublingual Semaglutide Drops: What the Evidence Shows
Drops, lozenges and under-the-tongue tablets are compounded products backed only by animal studies. Even the approved Wegovy tablet needs an absorption enhancer, an empty stomach and a far larger dose than the shot. What the studies show, and what sellers charge.
Read the analysis→ - Data investigation8 min · 12 sources
Retatrutide Price and Release Date: What Is Known
Lilly gives a filing quarter, not a launch date, and says retatrutide cannot be legally sold. Here is what is on sale anyway and what FDA has done about it.
Read the analysis→ - Data investigation7 min · 11 sources
Is There a Tirzepatide Pill? What Sellers Ship
All approved tirzepatide products are injections. The tablets, drops and lozenges sold online are compounded, have not been reviewed by FDA, and have never been tested in people.
Read the analysis→ - Scientific deep-dive8 min · 13 sources
Metformin and a GLP-1 Together: The Risk Is Not the One People Expect
Being on metformin did not raise stomach side effects when a GLP-1 started, across 16,996 trial participants. Low blood sugar comes from insulin and sulfonylureas, not metformin. Where the two drugs meet is dehydration: GLP-1 labels warn of kidney injury after vomiting, and kidney impairment is metformin's route to lactic acidosis.
Read the analysis→ - Scientific deep-dive9 min · 16 sources
GLP-1 Diarrhea: Why It Doesn't Follow the Dose, and What Has Actually Been Tested
In STEP UP, diarrhea was 27.3% at 7.2 mg semaglutide and 27.9% at 2.4 mg while vomiting rose. In SURMOUNT-5 it was 88 cases on each drug. Episodes last about three days but recur for months, the mechanism is unknown, and no trial has tested loperamide, diet or anything else for it.
Read the analysis→ - Scientific deep-dive9 min · 24 sources
Why a GLP-1 Raises Your Heart Rate, and When Palpitations Matter
The heart-rate warning follows the brand, not the size of the effect: Mounjaro has none, yet 10% on 15 mg had a fast sinus rhythm with a rise of at least 15 bpm, against 4.3% on placebo. On Wegovy, 26% saw their resting rate climb by at least 20 bpm on one or more visits. The rise lasts while the drug does and reverses when it stops.
Read the analysis→ - Scientific deep-dive8 min · 20 sources
Joint Pain, Back Pain and Aches on a GLP-1: What the Trials Counted
In STEP 1, back pain was 8.1% on semaglutide and 8.1% on placebo; on Ozempic, joint pain was less common than on placebo. STEP UP at 7.2 mg is the exception. The labeled pain signal is skin pain, dysesthesia, in 22% of people on Wegovy 7.2 mg, and it clears faster when the dose is changed.
Read the analysis→ - Scientific deep-dive8 min · 16 sources
Stomach Pain on a GLP-1: What Is Expected and What Is a Warning Sign
The label figures are bundles: Wegovy's 20% counts seven kinds of stomach pain, and the single term in the STEP trials was 8.8% against 4.3%. New pain on a settled dose was far less common. Nobody has measured how long the pain lasts or tested a treatment for it, and the smaller-meals advice is on no FDA label.
Read the analysis→ - Scientific deep-dive7 min · 9 sources
Dizzy on a GLP-1? The Blood-Pressure Question the Labels Skip
Dizziness usually traces to falling blood pressure, low blood sugar or the first weeks of a dose increase. On Zepbound, low blood pressure was 2.2% in people on blood-pressure medicines against 1.2% without; in the STEP trials 17.7% stopped all their blood-pressure pills on semaglutide, and the authors note there are no guidelines for doing it.
Read the analysis→ - Scientific deep-dive6 min · 4 sources
Creatine on a GLP-1: The Trial Nobody Has Run
Creatine is the most-studied supplement in sports nutrition and it has never been tested in anyone taking these drugs. The indirect case is real but conditional: the benefit named is strength, it sits on top of resistance training and adequate protein, and the DXA lean-mass figure used to sell it counts water creatine adds.
Read the analysis→ - Scientific deep-dive7 min · 4 sources
GLP-1s During Ramadan: What the Four Studies Actually Tested
The reassuring hypoglycemia numbers are real, and they are measured against sulfonylureas rather than against not fasting. Nobody has studied a person taking a GLP-1 purely for weight loss through a month of dry fasting. What the CGM data does show is that the trouble sits after iftar, not during the fast.
Read the analysis→ - Scientific deep-dive6 min · 2 sources
GLP-1s and Autoimmune Thyroiditis: An Association, and the Reason to Doubt It
The hazard ratio is 1.30 with a tight confidence interval across 290,770 matched patients per arm, which is hard to dismiss as noise. It is also exactly the shape detection bias makes: one arm was prompted toward thyroid testing by a boxed warning and the other was not. This is not the thyroid cancer warning, and the two get confused constantly.
Read the analysis→ - Scientific deep-dive7 min · 4 sources
GLP-1 Drugs and Quitting Smoking: What the Trials Actually Tested
Two randomized trials and one headline study disagree, and the disagreement is the story. The bigger trial found no effect on quitting and a real effect on weight; its own 12-month follow-up found the weight advantage gone. The widely-reported semaglutide result counted medical appointments, not cigarettes.
Read the analysis→ - Scientific deep-dive7 min · 4 sources
Plant-Based Protein on a GLP-1: What Closes the Gap, and Why the Drug Widens It
Two findings that look contradictory are both real: measured one meal at a time, an omnivorous meal beat a matched vegan meal by about 47%; measured over ten weeks at roughly 2 g/kg/day, neither diet was ahead. The catch is the dose, and appetite suppression is the thing standing in its way.
Read the analysis→ - Data investigation6 min · 4 sources
Generic GLP-1s: Eleven for Liraglutide, and None You Can Buy for Semaglutide
Counted from FDA’s own application database rather than from any announcement: eleven marketable generics for liraglutide, one for exenatide, none for tirzepatide or dulaglutide, and for semaglutide a single tentative approval that cannot legally be sold. Anything advertised as “generic semaglutide” is something else.
Read the analysis→ - Scientific deep-dive6 min · 2 sources
GLP-1 Drugs and HIV-Associated Lipohypertrophy: The Randomized Evidence
A condition described for two decades as hard to treat now has a double-blind, placebo-controlled trial behind it. Visceral fat fell about 30.6% against placebo over 32 weeks. A companion study measured what that cost in muscle, and then measured whether it mattered.
Read the analysis→ - Scientific deep-dive6 min · 2 sources
GLP-1 Drugs, Diabetic Foot Ulcers and Blood Flow to the Foot
One small randomized trial measured a mechanism — oxygen actually reaching the foot — and one large records study measured the outcome that matters, amputation. Neither settles it alone, and the cohort's own authors say causation cannot be inferred. Together they point the same way.
Read the analysis→ - Scientific deep-dive6 min · 2 sources
GLP-1 Drugs and Opioid Use Disorder: What the Records Data Shows
Two large observational studies point the same way: lower recorded opioid overdose rates, and a higher chance of entering remission among people already on methadone. Both are associations from health records. Neither displaces buprenorphine or methadone, and no trial has been run.
Read the analysis→ - Scientific deep-dive6 min · 2 sources
GLP-1 Drugs and the Gut Microbiome: What 38 Studies Could Not Agree On
That GLP-1s change gut bacteria is agreed. How they change them is not: the direction differs by drug, between animals and people, and for semaglutide points two ways at once. There is no clinical action to take from any of it, which is exactly why it is worth writing down.
Read the analysis→
How we work
A figure in an investigation was read off the seller’s own page on a recorded date. A clinical statement traces to PubMed, an FDA document, or the trial paper itself, and never to a press release, a listicle or another comparison site. Where two sources disagree we say so on the page instead of picking the tidier one. An article gets revisited when the evidence under it moves, though we will not pretend that happens the instant a study lands.
Nothing here is a recommendation to take a particular drug, and none of it can weigh your history the way a clinician can. Take the decision to one. How we rate sellers →